CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myelomaInger S. Nijhof, Niels W.C.J. van de Donk|Blood|2016Cited by 377
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumabInger S. Nijhof, Niels W.C.J. van de Donk|Leukemia|2015Cited by 266
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell MalignanciesHilma J. van der Horst, Martine E.D. Chamuleau, Inger S. Nijhof et al.|Cancers|2020Cited by 72
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled TrialSammy Huygens, Jarom Heijmans, Inger S. Nijhof et al.|The Journal of Infectious Diseases|2022Cited by 27
SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trialSammy Huygens, Jarom Heijmans, Quincy Hofsink et al.|medRxiv|2022Cited by 1